Fixed dose com­bi­na­tion and single administration analysis [General Sta­tis­tics]

posted by BRN – Turkey, 2015-07-15 12:21 (3496 d 17:33 ago) – Posting: # 15086
Views: 5,995

(edited on 2015-07-15 16:44)

Dear All,

We have a BE study for a fixed dose combination (FDC) product (T) which does not have an original reference. So our reference product (R) becomes administration of R1 and R2 in combination (R=R1+R2). However in other periods these original products are administered as monotherapy as per local regulations.

The protocol mentions the BE conclusion will be based on T vs. R.

Now my question is, what's the best approach for the statistical analysis?
  1. Treat the study as 2 period with T vs. R and code accordingly:
    (Treatments= T, R; Periods= 1, 2; Sequence= TR, RT).

  2. Treat the study as 3 period with T vs. R and R1 since R2 will not have one of the active ingredients, and code accordingly:
    (Treatments=T, R, R1; Periods: 1, 2, 3; Sequence:TRR1, TR1R, R1RT)

  3. Treat the study as 4 period with T vs. R, R1, and R2, and code accordingly:
    (Treatments=T, R, R1, R2; Periods: 1, 2, 3, 4; Sequence:TRR1R2, RR1TR2, ....)

From my point of view the best approach will be the first option but I'd like to hear some expert comments. Is there any other options, suggestions?

Thank you in advance for your kind support.

Regards,
BRN

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,665 registered users;
142 visitors (0 registered, 142 guests [including 8 identified bots]).
Forum time: 04:54 CET (Europe/Vienna)

There are sadistic scientists who hurry to hunt down errors
instead of establishing the truth.    Marie Curie

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5